Compounds > spironolactone
Page last updated: 2024-11-07

spironolactone and Disease Models, Animal

spironolactone has been researched along with Disease Models, Animal in 176 studies

Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.

Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.

Research Excerpts

ExcerptRelevanceReference
"A marked reduction of overall mortality in patients with severe congestive heart failure (CHF) has been demonstrated by addition of the mineralocorticoid receptor antagonist spironolactone to ACE inhibition."9.09Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES. ( Bauersachs, J; Christ, M; Ertl, G; Fraccarollo, D; Gretz, N; Wehling, M, 2000)
"The impact of low-dose spironolactone (LSPL) on polycystic ovarian syndrome (PCOS)-associated cardio-renal disorder is unknown."8.12Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model. ( Akintayo, CO; Areloegbe, SE; Aturamu, A; Olaniyi, KS; Oniyide, AA; Peter, MU, 2022)
"The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats."7.96Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020)
"In this study, we examined whether spironolactone (SP) could inhibit doxorubicin (DOX)-induced cardiotoxicity in the rat heart."7.83Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats. ( Chen, C; Dong, Z; Hou, T; Liu, G; Liu, Y; Wang, R; Zheng, S, 2016)
"Dogs subjected to RVP for 8 weeks in the absence or presence of eplerenone treatment during the final 4 weeks of pacing were assessed by echocardiography, electrophysiology study,ventricular fibrosis measurements, and inflammatory cytokine mRNA expression analysis."7.80Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure. ( , 2014)
"A chronic increase in circulating angiotensin II (Ang II) activates an aldosterone-mineralocorticoid receptor-ouabain neuromodulatory pathway in the brain that increases neuronal activation in hypothalamic nuclei, such as the paraventricular nucleus (PVN) and causes progressive hypertension."7.79Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension. ( Gabor, A; Leenen, FH, 2013)
" However, eplerenone inhibited the development of renal fibrosis, inflammation (macrophage and monocyte infiltration), interstitial cell proliferation, and activation of interstitial cells (α-SMA expression)."7.79Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. ( Chen, H; Liu, Y; Shao, Y; Sun, F; Yoshimura, A; Zhong, X, 2013)
"Although spironolactone and telmisartan are reported to reduce the risk of morbidity and death, direct studies on their effects on isoproterenol-induced cardiac hypertrophy are scanty."7.78Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy. ( Goyal, BR; Mehta, AA, 2012)
"These results suggest that intrathecal delivery spironolactone has therapeutic effects on radicular pain in rats."7.78Intrathecal injection of spironolactone attenuates radicular pain by inhibition of spinal microglia activation in a rat model. ( Bo, J; Gu, X; Liu, C; Ma, Z; Peng, L; Sun, X; Sun, YE; Yang, D; Zheng, Y; Zhu, B, 2012)
"The beneficial effects of eplerenone, a specific mineralocorticoid receptor blocker, were previously demonstrated in early atherosclerosis (ATS)."7.78Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice. ( Coleman, R; Gamliel-Lazarovich, A; Keidar, S; Raz-Pasteur, A, 2012)
"This study aimed to test the feasibility of spironolactone treatment in comparison with a surfactant in the early stage of acute respiratory distress syndrome (ARDS) in rats, as assessed by the acute lung injury (ALI) score, blood gas, brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP)."7.76The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats. ( Atalay, C; Aykan, S; Dogan, N; Gundogdu, C; Keles, MS, 2010)
" The aim of this study was to investigate whether eplerenone, a selective aldosterone receptor antagonist, has anti-inflammatory effects on viral myocarditis."7.75Anti-inflammatory effects of eplerenone on viral myocarditis. ( Hu, D; Liu, W; Matsumori, A; Shimada, M; Xiao, J, 2009)
"To investigate the effects of perindopril and spirolactone on plasma aldosterone (Ald) and left atrial remodeling and function in a canine model of atrial fibrillation (AF)."7.75[Effects of perindopril and spirolactone on plasma aldosterone and left atrial remodeling in a canine model of atrial fibrillation]. ( DU, X; Lei, T; Liu, XH; Liu, XP; Luo, TY; Shi, JH; Wang, HY, 2009)
" Spironolactone, a mineralocorticoid receptor antagonist, decreases ischemic cerebral infarct size in male spontaneously hypertensive stroke-prone rats (SHRSP)."7.74Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. ( Dorrance, AM; Pollock, DM; Rigsby, CS, 2007)
" To elucidate its significance for myocardial fibrosis in the hypertensive heart, we used a mouse model with infusion of angiotensin II and examined results by histology, immunohistochemistry, in situ hybridization, and quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR)."7.74Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. ( Hiroe, M; Imanaka-Yoshida, K; Inada, H; Nishioka, T; Onishi, K; Suzuki, M; Takakura, N; Yoshida, T, 2007)
" The combination of AGLD (5 mg/kg) with phenobarbital (PB, applied at its subeffective dose of 15 mg/kg) significantly shortened motor seizure and afterdischarge duration in amygdala-kindled seizures."7.73Aminoglutethimide but not spironolactone enhances the anticonvulsant effect of some antiepileptics against amygdala-kindled seizures in rats. ( Borowicz, KK; Czuczwar, SJ, 2005)
"We documented chronic ventricular arrhythmias in a first group of 58 rats after myocardial infarction (MI), then assessed the effects of spironolactone and fosinopril on morphological indexes and arrhythmias in a second group (n = 33)."7.71Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. ( Beck, L; Blanc-Guillemaud, V; Cherif, OK; Davy, JM; Jover, B, 2001)
"Eplerenone has been reported to have anti-hypertensive and protective effects on cardiovascular and renal injury in salt-sensitive hypertensive animal models, such as the Dahl salt-sensitive (DS) hypertensive rat and leptin receptor-deficient spontaneously hypertensive rat (SHR/cp)."6.45Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension. ( Takeda, Y, 2009)
"Spironolactone treatment reverted hyperphosphorylation of activated Erbb4 in these mice."5.46Spironolactone is an antagonist of NRG1-ERBB4 signaling and schizophrenia-relevant endophenotypes in mice. ( Brzózka, MM; Falkai, P; Herholt, A; Hinrichs, W; Kravchenko, M; Nave, KA; Papiol, S; Rossner, MJ; Schwab, MH; Soto-Bernardini, MC; Unterbarnscheidt, T; Wehr, MC; Wichert, SP; Wintgens, JP; Zhang, M; Zhang, W, 2017)
"Spironolactone treatment significantly decreased coronary TRPC expression and dysfunctions in MetS pigs."5.46Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs. ( Alloosh, M; Beli, E; Chakraborty, S; Chen, X; Grant, MB; Hiett, SC; Li, W; Long, X; Obukhov, AG; Riley, AM; Sturek, M; Temm, CJ; White, FA, 2017)
"Treatment with spironolactone either before or after ischemia prevented subsequent CKD by avoiding the activation of fibrotic and inflammatory pathways."5.39Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. ( Barrera-Chimal, J; Bobadilla, NA; Gamba, G; Pérez-Villalva, R; Reyna, J; Rodríguez-Romo, R; Uribe, N, 2013)
"Spironolactone treatment reversed the increased expression of caspase-3, bax, calpain I and MMP-9 and the decreased level of Bcl-2, calpastatin and TIMP-1, induced by chronic atrial pacing."5.36Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. ( Gong, Y; Li, J; Li, W; Li, Y; Shan, H; Yang, B; Zhao, J, 2010)
"The hypertension was not different and virtually superimposable in WT vs."5.35The role of aldosterone in mediating the dependence of angiotensin hypertension on IL-6. ( Brands, MW; Cannon, JG; Schreihofer, DA; Sturgis, LC, 2009)
"Proteinuria was prominent in SHR/NDmcr-cp compared with nonobese SHR, which was accompanied by podocyte injury as evidenced by foot process effacement, induction of desmin and attenuation of nephrin."5.33Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. ( Ando, K; Fujita, T; Gotoda, T; Nagase, M; Nagase, T; Shibata, S; Yoshida, S, 2006)
"Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure."5.32Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003)
"Eplerenone is a novel selective aldosterone blocker."5.31Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. ( Goldstein, S; McMahon, EG; Mishima, T; Morita, H; Rudolph, AE; Sabbah, HN; Sharov, VG; Suzuki, G; Tanhehco, EJ; Todor, A, 2002)
"A marked reduction of overall mortality in patients with severe congestive heart failure (CHF) has been demonstrated by addition of the mineralocorticoid receptor antagonist spironolactone to ACE inhibition."5.09Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES. ( Bauersachs, J; Christ, M; Ertl, G; Fraccarollo, D; Gretz, N; Wehling, M, 2000)
" Eplerenone, a mineralocorticoid-receptor antagonist with minimal binding to the progesterone and androgen receptors, is now licensed for treatment of heart failure in Europe and heart failure and hypertension in the US; it has also been proposed as a treatment for a variety of cardiovascular conditions."4.84Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. ( Connell, JM; McInnes, GT; McManus, F, 2008)
" However, although aldosterone receptor antagonism reduces mortality in patients with congestive heart failure, the progestational and antiandrogenic side effects of the nonspecific aldosterone receptor antagonist, spironolactone, have limited its usefulness in the treatment of hypertension."4.82Eplerenone: cardiovascular protection. ( Brown, NJ, 2003)
"The impact of low-dose spironolactone (LSPL) on polycystic ovarian syndrome (PCOS)-associated cardio-renal disorder is unknown."4.12Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model. ( Akintayo, CO; Areloegbe, SE; Aturamu, A; Olaniyi, KS; Oniyide, AA; Peter, MU, 2022)
"The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats."3.96Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020)
"To identify the effects of diuretic agents on adverse cardiac remodeling in CHF, this study was carried out, where we have compared the effects of torasemide and spironolactone in a rat model of dilated cardiomyopathy induced by porcine cardiac myosin-mediated experimental autoimmune myocarditis."3.85Comparative evaluation of torasemide and spironolactone on adverse cardiac remodeling in a rat model of dilated cardiomyopathy. ( Arumugam, S; Harima, M; Karuppagounder, V; Nakamura, M; Sone, H; Sreedhar, R; Suzuki, H; Watanabe, K, 2017)
"Hyperoxaluria was induced in male SD rats by administering ethylene glycol."3.83Involvement of renin-angiotensin-aldosterone system in calcium oxalate crystal induced activation of NADPH oxidase and renal cell injury. ( Khan, SR; Peck, AB; Shimizu, N; Sunil, J; Tsuji, H; Uemura, H; Wang, W; Yoshimura, K, 2016)
"In this study, we examined whether spironolactone (SP) could inhibit doxorubicin (DOX)-induced cardiotoxicity in the rat heart."3.83Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats. ( Chen, C; Dong, Z; Hou, T; Liu, G; Liu, Y; Wang, R; Zheng, S, 2016)
" β-AR overstimulation with associated cardiac hypertrophy and increased vasoconstrictor response to phenylephrine in aorta were modeled in rats by 7-day isoproterenol treatment."3.83Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by β-Adrenergic Overstimulation: Role of Perivascular Adipose Tissue. ( Alonso, MJ; Clerici, SP; Davel, AP; Jaffe, IZ; Palacios, R; Rossoni, LV; Vassallo, DV; Victorio, JA, 2016)
"Angiotensin II (Ang II) and aldosterone contribute to hypertension, oxidative stress and cardiovascular damage, but the contributions of aldosterone during Ang II-dependent hypertension are not well defined because of the difficulty to assess each independently."3.81Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats. ( Conte, D; Minas, JN; Nishiyama, A; Ortiz, RM; Thorwald, MA; Vázquez-Medina, JP, 2015)
"Dogs subjected to RVP for 8 weeks in the absence or presence of eplerenone treatment during the final 4 weeks of pacing were assessed by echocardiography, electrophysiology study,ventricular fibrosis measurements, and inflammatory cytokine mRNA expression analysis."3.80Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure. ( , 2014)
"Microvessel density increased in varicocele group and spironolactone inhibited angiogenesis neither by antimineralocorticoid, nor by antiandrogenic effect."3.80Angiogenesis inhibition impairs testicular morphology in experimental left varicocele rat model. ( Çaylak, B; Erdem, ŞR; Gökhan-Köse, M; Peşkircioğlu, ÇL, 2014)
" The MR/GR agonist 6-α methylprednisolone, commonly injected for low back pain, reduced mechanical hypersensitivity when applied locally to the DRG but was less effective than fluticasone."3.80Blocking the mineralocorticoid receptor improves effectiveness of steroid treatment for low back pain in rats. ( Strong, JA; Xie, W; Ye, L; Zhang, JM, 2014)
"A chronic increase in circulating angiotensin II (Ang II) activates an aldosterone-mineralocorticoid receptor-ouabain neuromodulatory pathway in the brain that increases neuronal activation in hypothalamic nuclei, such as the paraventricular nucleus (PVN) and causes progressive hypertension."3.79Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension. ( Gabor, A; Leenen, FH, 2013)
" However, eplerenone inhibited the development of renal fibrosis, inflammation (macrophage and monocyte infiltration), interstitial cell proliferation, and activation of interstitial cells (α-SMA expression)."3.79Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. ( Chen, H; Liu, Y; Shao, Y; Sun, F; Yoshimura, A; Zhong, X, 2013)
"Although spironolactone and telmisartan are reported to reduce the risk of morbidity and death, direct studies on their effects on isoproterenol-induced cardiac hypertrophy are scanty."3.78Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy. ( Goyal, BR; Mehta, AA, 2012)
"These results suggest that intrathecal delivery spironolactone has therapeutic effects on radicular pain in rats."3.78Intrathecal injection of spironolactone attenuates radicular pain by inhibition of spinal microglia activation in a rat model. ( Bo, J; Gu, X; Liu, C; Ma, Z; Peng, L; Sun, X; Sun, YE; Yang, D; Zheng, Y; Zhu, B, 2012)
"The beneficial effects of eplerenone, a specific mineralocorticoid receptor blocker, were previously demonstrated in early atherosclerosis (ATS)."3.78Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice. ( Coleman, R; Gamliel-Lazarovich, A; Keidar, S; Raz-Pasteur, A, 2012)
" Here, tonic-clonic seizures were induced with a convulsive dose of pentylenetetrazole (PTZ), and acute seizure recurrence was evoked with a subconvulsive dose of the drug."3.76Stress within the postseizure time window inhibits seizure recurrence. ( Cao, J; Duan, TT; Mao, RR; Tan, JW; Tian, M; Xu, L; Zhou, QX, 2010)
"This study aimed to test the feasibility of spironolactone treatment in comparison with a surfactant in the early stage of acute respiratory distress syndrome (ARDS) in rats, as assessed by the acute lung injury (ALI) score, blood gas, brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP)."3.76The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats. ( Atalay, C; Aykan, S; Dogan, N; Gundogdu, C; Keles, MS, 2010)
" Hypothesising that selective MR antagonism might also influence atrial ion currents (L-type calcium current [I (Ca,L)], transient outward potassium current [I (to)], sustained outward potassium current [I (sus)]) and their tachycardia-induced remodelling, the effects of an eplerenone treatment were studied in a rabbit model."3.76Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits. ( Bentz, K; Eick, C; Kettering, K; Konior, A; Laszlo, R; Schreieck, J; Schreiner, B, 2010)
" The aim of this study was to investigate whether eplerenone, a selective aldosterone receptor antagonist, has anti-inflammatory effects on viral myocarditis."3.75Anti-inflammatory effects of eplerenone on viral myocarditis. ( Hu, D; Liu, W; Matsumori, A; Shimada, M; Xiao, J, 2009)
"This study's aim was to determine whether chronic eplerenone treatment protects against detrimental ventricular electrical remodeling and development of an arrhythmogenic substrate in a rapid ventricular pacing (RVP)-induced heart failure model."3.75Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure. ( Hoeker, G; Laurita, KR; Martovitz, NL; Shroff, SC; Stambler, BS, 2009)
"To investigate the effects of perindopril and spirolactone on plasma aldosterone (Ald) and left atrial remodeling and function in a canine model of atrial fibrillation (AF)."3.75[Effects of perindopril and spirolactone on plasma aldosterone and left atrial remodeling in a canine model of atrial fibrillation]. ( DU, X; Lei, T; Liu, XH; Liu, XP; Luo, TY; Shi, JH; Wang, HY, 2009)
" After 4 weeks of DOCA-salt hypertension, rats were either killed (n = 6), or treated with a non-hypotensive dose of spironolactone (n = 7) or triple therapy (hydrochlorothiazide, reserpine and hydralazine, n = 8) to normalize blood pressure or with vehicle (n = 19) for two further weeks."3.74Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. ( Cordasic, N; Hartner, A; Hilgers, KF; Klanke, B; Schmieder, RE; Veelken, R, 2008)
" Spironolactone, a mineralocorticoid receptor antagonist, decreases ischemic cerebral infarct size in male spontaneously hypertensive stroke-prone rats (SHRSP)."3.74Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. ( Dorrance, AM; Pollock, DM; Rigsby, CS, 2007)
" To elucidate its significance for myocardial fibrosis in the hypertensive heart, we used a mouse model with infusion of angiotensin II and examined results by histology, immunohistochemistry, in situ hybridization, and quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR)."3.74Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. ( Hiroe, M; Imanaka-Yoshida, K; Inada, H; Nishioka, T; Onishi, K; Suzuki, M; Takakura, N; Yoshida, T, 2007)
"The spironolactone Y5 antagonist significantly reduced body weight in C57BL DIO mice, but not in Npy5r(-/-) DIO mice."3.74Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. ( Fukami, T; Gomori, A; Ishihara, A; Ito, J; Iwaasa, H; Kanatani, A; Kitazawa, H; MacNeil, DJ; Mashiko, S; Matsushita, H; Mitobe, Y; Moriya, R; Takahashi, T; Van der Ploeg, LH, 2008)
" The combination of AGLD (5 mg/kg) with phenobarbital (PB, applied at its subeffective dose of 15 mg/kg) significantly shortened motor seizure and afterdischarge duration in amygdala-kindled seizures."3.73Aminoglutethimide but not spironolactone enhances the anticonvulsant effect of some antiepileptics against amygdala-kindled seizures in rats. ( Borowicz, KK; Czuczwar, SJ, 2005)
"We hypothesized that the increased urinary Ca2+ and Mg2+ excretion and bone loss that accompanies aldosteronism is aggravated with furosemide and is attenuated by spironolactone."3.73Diuretics and bone loss in rats with aldosteronism. ( Bhattacharya, SK; Chhokar, VS; Law, PH; Sun, Y; Weber, KT, 2005)
" Aldosterone itself has been shown to increase cardiovascular fibrosis, therefore, we studied the suppressive effects of eplerenone, a new aldosterone receptor antagonist, on neointimal hyperplasia after coronary stent implantation in swine."3.73Eplerenone suppresses neointimal formation after coronary stent implantation in swine. ( Iso, Y; Katagiri, T; Sato, T; Suzuki, H; Takeyama, Y; Wakabayashi, K, 2006)
"To evaluate the role of spironolactone in myocardial remodelling in a Chagas cardiomyopathy model."3.73Aldosterone antagonism in an inflammatory state: evidence for myocardial protection. ( Billate, A; Fernandes, F; Ianni, BM; Mady, C; Martins, DG; Neto, EC; Ramires, FJ; Salemi, VM, 2006)
"In mice with MI, eplerenone attenuates progression of heart failure comparably to ACEi, and its effect is independent of BP lowering."3.72Role of a selective aldosterone blocker in mice with chronic heart failure. ( Carretero, OA; Liu, YH; Peterson, E; Rhaleb, NE; Rudolph, AE; Wang, D; Xu, J; Yang, XP, 2004)
"We documented chronic ventricular arrhythmias in a first group of 58 rats after myocardial infarction (MI), then assessed the effects of spironolactone and fosinopril on morphological indexes and arrhythmias in a second group (n = 33)."3.71Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. ( Beck, L; Blanc-Guillemaud, V; Cherif, OK; Davy, JM; Jover, B, 2001)
"Spironolactone and standard-dose RU 486 did not modify adrenocorticotrophin-induced hypertension despite demonstrable antimineralocorticoid and antiglucocorticoid actions."3.70Adrenocorticotrophin-induced hypertension: effects of mineralocorticoid and glucocorticoid receptor antagonism. ( Fraser, T; Li, M; Wen, C; Whitworth, JA, 1999)
"We have previously demonstrated that baroreceptor discharge sensitivity is depressed in dogs with experimental heart failure and that this depressed sensitivity can be reversed by the Na+,K(+)-ATPase inhibitor ouabain."3.68Aldosterone reduces baroreceptor discharge in the dog. ( McClain, JM; Wang, W; Zucker, IH, 1992)
"Eplerenone has been reported to have anti-hypertensive and protective effects on cardiovascular and renal injury in salt-sensitive hypertensive animal models, such as the Dahl salt-sensitive (DS) hypertensive rat and leptin receptor-deficient spontaneously hypertensive rat (SHR/cp)."2.45Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension. ( Takeda, Y, 2009)
"Hypertension results in left ventricular hypertrophy and cardiac dysfunction."1.51Myocardial global longitudinal strain: An early indicator of cardiac interstitial fibrosis modified by spironolactone, in a unique hypertensive rat model. ( Coffey, S; Leader, CJ; Moharram, M; Sammut, IA; Walker, RJ; Wilkins, GW, 2019)
"Spironolactone treatment reverted hyperphosphorylation of activated Erbb4 in these mice."1.46Spironolactone is an antagonist of NRG1-ERBB4 signaling and schizophrenia-relevant endophenotypes in mice. ( Brzózka, MM; Falkai, P; Herholt, A; Hinrichs, W; Kravchenko, M; Nave, KA; Papiol, S; Rossner, MJ; Schwab, MH; Soto-Bernardini, MC; Unterbarnscheidt, T; Wehr, MC; Wichert, SP; Wintgens, JP; Zhang, M; Zhang, W, 2017)
"Spironolactone treatment significantly decreased coronary TRPC expression and dysfunctions in MetS pigs."1.46Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs. ( Alloosh, M; Beli, E; Chakraborty, S; Chen, X; Grant, MB; Hiett, SC; Li, W; Long, X; Obukhov, AG; Riley, AM; Sturek, M; Temm, CJ; White, FA, 2017)
"Pharmacological treatment for heart failure involves different drugs as: angiotensin-converting enzyme inhibitors, B-adrenergic blockers, digitalis glycosides and diuretics."1.46[Analysis of the mitochondrial function and ultrastructure in healthy albino mice treated with heart failure medications] ( Baez, A; Bazán, C; Camino Willhuber, GO; Fretes, R; Guzman Mentesana, G; Lo Presti, S; Paglini-Oliva, PA; Rivarola, HW; Strauss, M, 2017)
"Brain edema was measured on day 5 by MRI, histochemical staining of brain sections and tissue water content determination (n=7, each experiment)."1.43Treadmill exercise ameliorates ischemia-induced brain edema while suppressing Na⁺/H⁺ exchanger 1 expression. ( Aono, H; Choudhury, ME; Fujita, T; Islam, A; Mise, A; Miyanishi, K; Nishioka, R; Sugimoto, K; Takahashi, H; Takeda, H; Tanaka, J; Yano, H, 2016)
"Plasma aldosterone is elevated in type 2 diabetes and obesity in experimental and clinical studies and can act to inhibit both glucose-stimulated insulin secretion by the β-cell and insulin signaling."1.43Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats. ( Bornstein, SR; Brown, NF; Brunssen, C; Deussen, A; Eisenhofer, G; Engelmann, F; Hofmann, A; Huber, J; Jannasch, A; Martin, M; Mittag, J; Morawietz, H; Peitzsch, M; Streicher, R; Weldon, SM, 2016)
"Spinal and bulbar muscular atrophy is caused by polyglutamine expansion in the androgen receptor."1.43Sexual Reassignment Fails to Prevent Kennedy's Disease. ( Badders, NM; Bakar, D; Bott, LC; Burke, A; Fischbeck, KH; Grunseich, C; Harmison, GG; Joe, GO; Kokkinis, A; Lanman, TA; Schindler, AB; Shrader, JA; Taylor, JP, 2016)
"This agent could be useful for the treatment of hypertension, cardiovascular and renal disorders."1.42Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. ( Aoki, K; Arai, K; Homma, T; Ishikawa, H; Mizuno, M; Morikawa, Y; Sada, T; Tsuruoka, H; Ubukata, N, 2015)
"In experimental hyperaldosteronism, the increase in Gal-3 expression was associated with cardiac inflammation and fibrosis, alterations that were prevented by Gal-3 blockade independently of blood pressure levels."1.42Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. ( Cachofeiro, V; Calvier, L; Fernández-Celis, A; Jaisser, F; Jurado-López, R; López-Andrés, N; Martínez-Martínez, E; Rossignol, P; Rossoni, LV; Rousseau, E; Zannad, F, 2015)
"Spironolactone treatment prevented Th17 cell activation and increased numbers of forkhead box P3-positive cells relative to DOCA-salt rats."1.40Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. ( Alzamora, R; Amador, CA; Barrientos, V; Carrasco, L; Figueroa, F; González, M; Herrada, AA; Kalergis, AM; Michea, L; Peña, J; Valdés, S, 2014)
"Finerenone reduced cardiac hypertrophy, plasma prohormone of brain natriuretic peptide, and proteinuria more efficiently than eplerenone when comparing equinatriuretic doses."1.40Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. ( Albrecht-Küpper, B; Bärfacker, L; Delbeck, M; Eitner, F; Hartmann, E; Kolkhof, P; Kretschmer, A; Schäfer, S; Steinke, W, 2014)
"Peritoneal fibrosis is a complication of patients with long-term continuous ambulatory peritoneal dialysis (CAPD)."1.40The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis. ( Ding, JL; Hao, JB; Hao, LR; Ren, LS; Zhang, L, 2014)
"Treatment with eplerenone (100 mg/kg/d) attenuated left ventricular hypertrophy and fully prevented fibrosis, dilatation, and failure."1.40Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation. ( Baba, HA; Frantz, S; Gaßner, B; Kuhn, M; Nakagawa, H; Nikolaev, VO; Oberwinkler, H; Saito, Y; Umbenhauer, S; Wagner, H, 2014)
"Corticosterone or vehicle was injected twice daily in rats from 8 to 12 weeks of age."1.39Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism. ( Hattori, T; Iwase, E; Miyachi, M; Murase, T; Murohara, T; Nagata, K; Ohtake, M; Takahashi, K; Tsuboi, K, 2013)
"Treatment with spironolactone either before or after ischemia prevented subsequent CKD by avoiding the activation of fibrotic and inflammatory pathways."1.39Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. ( Barrera-Chimal, J; Bobadilla, NA; Gamba, G; Pérez-Villalva, R; Reyna, J; Rodríguez-Romo, R; Uribe, N, 2013)
"In addition, induction of cardiac hypertrophy by ISO caused remarkable induction in CT-1 mRNA and protein expression levels by approximately 3."1.39Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection. ( Al-Mazroua, HA; Al-Rasheed, NM; Korashy, HM, 2013)
"With a long (60 min) stress-KA delay, seizures were suppressed through activation of a glucocorticosterone receptor (GR)."1.38Stress and corticosteroid modulation of seizures and synaptic inhibition in the hippocampus. ( Maggio, N; Segal, M, 2012)
"Spironolactone treatment decreased the total heart weight."1.38Effects of spironolactone treatment on an experimental model of chronic aortic valve regurgitation. ( Arsenault, M; Couet, J; Lachance, D; Roussel, E; Zendaoui, A, 2012)
"Spironolactone can enhance the analgesic effects of dexamethasone via complex mechanisms."1.37The respective and interaction effects of spinal GRs and MRs on radicular pain induced by chronic compression of the dorsal root ganglion in the rat. ( Gu, X; Liu, C; Ma, Q; Ma, Z; Peng, L; Song, L; Sun, X; Yang, D; Zheng, Y; Zhu, B, 2011)
"Nearly universal cardiomyopathy in Duchenne muscular dystrophy (DMD) contributes to heart failure and death."1.37Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. ( Canan, BD; Chimanji, NS; Delfín, DA; Ganguly, R; Janssen, PM; Martin, CD; Mays, TA; Murray, JD; Rafael-Fortney, JA; Raman, SV; Schill, KE; Stangland, JE; Tran, T; Xu, Y, 2011)
"Spironolactone treatment reversed all the above effects."1.37A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. ( Cachofeiro, V; Díez, J; Fortuno, MA; Lahera, V; López-Andrés, N; Martin-Fernandez, B; Rossignol, P; Zannad, F, 2011)
"Spironolactone treatment reversed the increased expression of caspase-3, bax, calpain I and MMP-9 and the decreased level of Bcl-2, calpastatin and TIMP-1, induced by chronic atrial pacing."1.36Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. ( Gong, Y; Li, J; Li, W; Li, Y; Shan, H; Yang, B; Zhao, J, 2010)
"Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart."1.36Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. ( Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA, 2010)
"Proteinuria was decreased in groups MR and AR compared with group P (on day 14 after PAN administration, respectively; group P vs AR, P < 0."1.36Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome. ( Fujimoto, S; Fukuda, A; Iwatsubo, S; Kawachi, H; Kitamura, K, 2010)
"Spironolactone treatment did not alter SBP."1.36The glucocorticoid receptor is required for experimental adrenocorticotrophic hormone-induced hypertension in mice. ( Cole, TJ; McKenzie, KU; Schyvens, CG; Vickers, JJ; Whitworth, JA; Zhang, Y, 2010)
"Male Wistar rats fed with an unrestricted sodium diet received CsA 15 mg/kg/day or CsA at the same dosage plus 20 mg/kg/day of spironolactone."1.35The effect of aldosterone antagonist in experimental nephropathy induced by cyclosporine A. ( Miorin, LA; Sens, YA; Silva, FM, 2008)
"Metabolic syndrome is a highly predisposing condition for cardiovascular disease and could be a cause of excess salt-induced organ damage."1.35Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. ( Ando, K; Fujita, M; Fujita, T; Kawarazaki, H; Matsui, H; Nagae, A; Nagase, M; Shimosawa, T, 2008)
"The hypertension was not different and virtually superimposable in WT vs."1.35The role of aldosterone in mediating the dependence of angiotensin hypertension on IL-6. ( Brands, MW; Cannon, JG; Schreihofer, DA; Sturgis, LC, 2009)
"Spironolactone has been noted to attenuate cardiac fibrosis."1.35Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. ( Bagrov, AY; Cooper, CJ; El-Okdi, N; Elkareh, J; Fedorova, OV; Gohara, S; Gupta, S; Haller, S; Malhotra, D; Periyasamy, SM; Shapiro, JI; Shidyak, A; Taleb, M; Tian, J; Xie, Z, 2009)
"Treatment with eplerenone at a dose of 1."1.34Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. ( Gao, XY; Horiuchi, M; Ide, A; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Okamoto, S; Tsukuda, K, 2007)
"The spironolactone treatment did not block normal glucocorticoid receptor-mediated immune-suppression functions because mice receiving prednisolone, either with or without spironolactone, maintained normal body weights, hematocrits, and serum immune complexes."1.33Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear. ( Gross, ND; Kempton, JB; Trune, DR, 2006)
"Proteinuria was prominent in SHR/NDmcr-cp compared with nonobese SHR, which was accompanied by podocyte injury as evidenced by foot process effacement, induction of desmin and attenuation of nephrin."1.33Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. ( Ando, K; Fujita, T; Gotoda, T; Nagase, M; Nagase, T; Shibata, S; Yoshida, S, 2006)
"Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure."1.32Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003)
"Thus, aldosteronism is associated with an activation of circulating immune cells induced by iterations in PBMC divalent cations and transduced by oxidative/nitrosative stress."1.32Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. ( Ahokas, RA; Bhattacharya, SK; Gerling, IC; Herring, PA; Lu, L; Postlethwaite, AE; Sun, Y; Warrington, KJ; Weber, KT; Wodi, LA, 2003)
"Spironolactone treatment decreased PAI-1 immunoreactivity and reduced in a dose-dependent fashion cardiac and renal damage."1.32Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. ( Adler, GK; Jonasson, L; Martinez-Vasquez, D; Mukasa, K; Oestreicher, EM; Roubsanthisuk, W; Stone, JR, 2003)
"Eplerenone is a novel selective aldosterone blocker."1.31Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. ( Goldstein, S; McMahon, EG; Mishima, T; Morita, H; Rudolph, AE; Sabbah, HN; Sharov, VG; Suzuki, G; Tanhehco, EJ; Todor, A, 2002)
"Although autoimmune sensorineural hearing loss can be effectively treated with corticosteroids, little is known about how these drugs affect cochlear function."1.31Spironolactone blocks glucocorticoid-mediated hearing preservation in autoimmune mice. ( Gross, ND; Kempton, JB; Trune, DR, 2002)
"Among the determinants of cardiac failure, the renin-angiotensin-aldosterone system has a central role, and antagonism of the mineralocorticoid receptor (MR) has been proposed as a therapeutic strategy."1.31Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. ( Beggah, AT; Bocchi, B; Cailmail, S; Delage, V; Delcayre, C; Escoubet, B; Farman, N; Jaisser, F; Ouvrard-Pascaud, A; Peuchmaur, M; Puttini, S, 2002)
"Spironolactone was able largely to prevent the perivascular/interstitial fibrosis and scarring in either model irrespective of the development of left ventricular hypertrophy and arterial hypertension."1.28Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. ( Brilla, CG; Weber, KT, 1992)

Research

Studies (176)

TimeframeStudies, this research(%)All Research%
pre-19905 (2.84)18.7374
1990's5 (2.84)18.2507
2000's66 (37.50)29.6817
2010's92 (52.27)24.3611
2020's8 (4.55)2.80

Authors

AuthorsStudies
Man, JJ1
Lu, Q1
Moss, ME1
Carvajal, B1
Baur, W1
Garza, AE1
Freeman, R1
Anastasiou, M1
Ngwenyama, N1
Adler, GK3
Alcaide, P1
Jaffe, IZ4
Peter, MU1
Areloegbe, SE1
Akintayo, CO1
Oniyide, AA2
Aturamu, A1
Olaniyi, KS2
Leader, CJ2
Moharram, M1
Coffey, S1
Sammut, IA2
Wilkins, GW1
Walker, RJ2
Wang, CC1
Lee, AS1
Liu, SH1
Chang, KC1
Shen, MY1
Chang, CT1
Wang, Y2
Zhong, B1
Wu, Q1
Zhu, T1
Zhang, M2
Krasnova, M1
Kulikov, A1
Okovityi, S1
Ivkin, D1
Karpov, A1
Kaschina, E1
Smirnov, A1
Kelly, DJ1
Wilkins, GT1
Balogh, DB1
Molnar, A1
Hosszu, A1
Lakat, T1
Hodrea, J1
Szabo, AJ1
Lenart, L1
Fekete, A1
Adeyanju, OA1
Ojulari, LS1
Omoaghe, AO1
Olaiya, OE1
Marzolla, V1
Feraco, A1
Limana, F1
Kolkhof, P4
Armani, A1
Caprio, M1
Arumugam, S1
Sreedhar, R1
Karuppagounder, V1
Harima, M2
Nakamura, M1
Suzuki, H2
Sone, H1
Watanabe, K2
Wehr, MC1
Hinrichs, W1
Brzózka, MM1
Unterbarnscheidt, T1
Herholt, A1
Wintgens, JP1
Papiol, S1
Soto-Bernardini, MC1
Kravchenko, M1
Nave, KA1
Wichert, SP1
Falkai, P1
Zhang, W1
Schwab, MH1
Rossner, MJ1
Li, W2
Chen, X1
Riley, AM1
Hiett, SC1
Temm, CJ1
Beli, E1
Long, X1
Chakraborty, S1
Alloosh, M1
White, FA1
Grant, MB1
Sturek, M1
Obukhov, AG1
Slavic, S1
Ford, K1
Modert, M1
Becirovic, A1
Handschuh, S1
Baierl, A1
Katica, N1
Zeitz, U1
Erben, RG1
Andrukhova, O1
Elinoff, JM1
Chen, LY1
Dougherty, EJ1
Awad, KS1
Wang, S1
Biancotto, A1
Siddiqui, AH1
Weir, NA1
Cai, R1
Sun, J1
Preston, IR1
Solomon, MA1
Danner, RL1
Yan, Y1
Wang, C1
Lu, Y1
Gong, H1
Wu, Z1
Ma, X1
Li, H1
Wang, B1
Zhang, X1
Zhu, JJ1
Chen, YP2
Yang, M1
Liu, BL1
Dong, J1
Dong, HR1
Rui, HL2
Cheng, H1
Dahmana, N1
Mugnier, T1
Gabriel, D1
Kaltsatos, V1
Bertaim, T1
Behar-Cohen, F1
Gurny, R1
Kalia, YN1
Brown, SM1
Meuth, AI1
Davis, JW1
Rector, RS1
Bender, SB3
Camino Willhuber, GO1
Guzman Mentesana, G1
Baez, A1
Lo Presti, S1
Bazán, C1
Strauss, M1
Fretes, R1
Paglini-Oliva, PA1
Rivarola, HW1
Barrera-Chimal, J2
Rocha, L1
Amador-Martínez, I1
Pérez-Villalva, R2
González, R1
Cortés-González, C1
Uribe, N2
Ramírez, V1
Berman, N1
Gamba, G2
Bobadilla, NA2
Dong, D1
Fan, TT1
Ji, YS1
Yu, JY1
Wu, S1
Zhang, L2
Hauck, JS1
Lowe, J2
Rastogi, N3
McElhanon, KE1
Petrosino, JM1
Peczkowski, KK1
Chadwick, AN1
Zins, JG2
Accornero, F1
Janssen, PML1
Weisleder, NL1
Rafael-Fortney, JA4
Gabor, A1
Leenen, FH3
Gamliel-Lazarovich, A2
Raz-Pasteur, A2
Coleman, R2
Keidar, S3
Hattori, T2
Murase, T2
Iwase, E1
Takahashi, K2
Ohtake, M4
Tsuboi, K1
Miyachi, M2
Murohara, T2
Nagata, K2
Liu, S1
Xie, Z2
Daugherty, A1
Cassis, LA1
Pearson, KJ1
Gong, MC1
Guo, Z1
Kurobe, H1
Hirata, Y1
Matsuoka, Y1
Sugasawa, N1
Higashida, M1
Nakayama, T1
Maxfield, MW1
Yoshida, Y2
Shimabukuro, M1
Kitagawa, T1
Sata, M1
Patel, BM1
Bhadada, SV1
Borgdorff, MA1
Bartelds, B1
Dickinson, MG1
Steendijk, P1
Berger, RM1
Ramírez, E1
Klett-Mingo, M1
Ares-Carrasco, S1
Picatoste, B1
Ferrarini, A1
Rupérez, FJ1
Caro-Vadillo, A1
Barbas, C1
Egido, J1
Tuñón, J1
Lorenzo, Ó1
Chen, H1
Sun, F1
Zhong, X1
Shao, Y1
Yoshimura, A1
Liu, Y2
Amador, CA1
Barrientos, V1
Peña, J1
Herrada, AA1
González, M2
Valdés, S1
Carrasco, L2
Alzamora, R1
Figueroa, F1
Kalergis, AM1
Michea, L2
Lavall, D1
Selzer, C1
Schuster, P1
Lenski, M1
Adam, O1
Schäfers, HJ1
Böhm, M1
Laufs, U1
Janssen, PM3
Murray, JD2
Schill, KE2
Schultz, EJ2
Tran, T2
Raman, SV3
Delbeck, M1
Kretschmer, A2
Steinke, W1
Hartmann, E2
Bärfacker, L1
Eitner, F1
Albrecht-Küpper, B1
Schäfer, S2
Gökhan-Köse, M1
Erdem, ŞR1
Peşkircioğlu, ÇL1
Çaylak, B1
Ye, L1
Xie, W1
Strong, JA1
Zhang, JM1
Hao, JB1
Ren, LS1
Ding, JL1
Hao, LR1
Nakagawa, H1
Oberwinkler, H1
Nikolaev, VO1
Gaßner, B1
Umbenhauer, S1
Wagner, H1
Saito, Y1
Baba, HA1
Frantz, S1
Kuhn, M1
Rafatian, N1
Westcott, KV1
White, RA2
Takatsu, M1
Watanabe, S1
Cheng, XW1
Navarro-Zaragoza, J1
Laorden, ML1
Milanés, MV1
Calvier, L2
Martinez-Martinez, E2
Miana, M1
Cachofeiro, V3
Rousseau, E2
Sádaba, JR1
Zannad, F4
Rossignol, P3
López-Andrés, N3
Ménard, J1
Rigel, DF1
Watson, C1
Jeng, AY2
Fu, F1
Beil, M1
Liu, J1
Chen, W1
Hu, CW1
Leung-Chu, J1
LaSala, D1
Liang, G1
Rebello, S1
Zhang, Y2
Dole, WP1
Sun, QL1
Li, M2
Lincevicius, GS1
Shimoura, CG1
Nishi, EE1
Perry, JC1
Casarini, DE1
Gomes, GN1
Bergamaschi, CT1
Campos, RR1
Pizarro, M1
Solís, N1
Quintero, P1
Barrera, F1
Cabrera, D1
Rojas-de Santiago, P1
Arab, JP1
Padilla, O1
Roa, JC1
Moshage, H1
Wree, A1
Inzaugarat, E1
Feldstein, AE1
Fardella, CE1
Baudrand, R1
Riquelme, A1
Arrese, M1
Jeewandara, TM1
Ameer, OZ1
Boyd, R1
Wyse, BF1
Underwood, CF1
Phillips, JK1
DeMarco, VG2
Padilla, J1
Jenkins, NT1
Habibi, J3
Garro, M2
Pulakat, L1
Aroor, AR2
Sowers, JR3
Bostick, B1
Jia, G1
Domeier, TL1
Lambert, MD1
Nistala, R1
Hayden, MR1
Ma, L1
Manrique, C1
Tsuji, H1
Wang, W2
Sunil, J1
Shimizu, N1
Yoshimura, K1
Uemura, H1
Peck, AB1
Khan, SR1
Yu, HD1
Xia, S1
Zha, CQ1
Deng, SB1
Du, JL1
She, Q1
Arai, K1
Homma, T1
Morikawa, Y1
Ubukata, N1
Tsuruoka, H1
Aoki, K1
Ishikawa, H1
Mizuno, M1
Sada, T1
Minas, JN1
Thorwald, MA1
Conte, D1
Vázquez-Medina, JP1
Nishiyama, A1
Ortiz, RM1
Fernández-Celis, A1
Jurado-López, R1
Rossoni, LV2
Jaisser, F2
Tatsumoto, N1
Yamada, S1
Tokumoto, M1
Eriguchi, M1
Noguchi, H1
Torisu, K1
Tsuruya, K1
Kitazono, T1
Ayuzawa, N2
Nagase, M5
Ueda, K2
Nishimoto, M1
Kawarazaki, W2
Marumo, T1
Aiba, A1
Sakurai, T1
Shindo, T1
Fujita, T7
Nishioka, R1
Sugimoto, K1
Aono, H1
Mise, A1
Choudhury, ME1
Miyanishi, K1
Islam, A1
Takeda, H1
Takahashi, H1
Yano, H1
Tanaka, J1
Grune, J1
Benz, V1
Brix, S1
Salatzki, J1
Blumrich, A1
Höft, B1
Klopfleisch, R1
Foryst-Ludwig, A1
Kintscher, U1
Liu, G1
Wang, R1
Hou, T1
Chen, C1
Zheng, S1
Dong, Z1
Zhu, D1
Rashdan, NA1
Chapman, KE1
Hadoke, PW1
MacRae, VE1
Jokinen, V1
Lilius, T1
Laitila, J1
Niemi, M1
Kambur, O1
Kalso, E1
Rauhala, P1
Victorio, JA1
Clerici, SP1
Palacios, R1
Alonso, MJ1
Vassallo, DV1
Davel, AP1
Xu, C1
Lu, A1
Wang, H2
Fang, H1
Zhou, L1
Sun, P1
Yang, T1
Hofmann, A1
Brunssen, C1
Peitzsch, M1
Martin, M1
Mittag, J1
Jannasch, A1
Engelmann, F1
Brown, NF1
Weldon, SM1
Huber, J1
Streicher, R1
Deussen, A1
Eisenhofer, G1
Bornstein, SR1
Morawietz, H1
Floyd, KT1
Chadwick, JA1
Swager, SA1
Kadakia, FK1
Smart, S1
Gomez-Sanchez, EP1
Gomez-Sanchez, CE1
Lanman, TA1
Bakar, D1
Badders, NM1
Burke, A1
Kokkinis, A1
Shrader, JA1
Joe, GO1
Schindler, AB1
Bott, LC1
Harmison, GG1
Taylor, JP1
Fischbeck, KH1
Grunseich, C1
Klanke, B1
Cordasic, N1
Hartner, A1
Schmieder, RE1
Veelken, R1
Hilgers, KF1
Shimosawa, T2
Matsui, H3
Kaneko, T1
Ogura, S1
Uetake, Y1
Takenaka, K1
Yatomi, Y1
Silva, FM1
Miorin, LA1
Sens, YA1
Graf, K1
Hucko, T1
Stawowy, P1
Villagrán, A1
Urzúa, A1
Kuntsmann, S1
Venegas, P1
Marusic, ET1
Ando, K2
Kawarazaki, H1
Nagae, A1
Fujita, M2
Qu, J1
Volpicelli, FM1
Garcia, LI1
Sandeep, N1
Zhang, J1
Márquez-Rosado, L1
Lampe, PD1
Fishman, GI1
Wei, Y1
Whaley-Connell, AT1
Rehmer, J1
Rehmer, N1
Patel, K1
Hayden, M1
DeMarco, V1
Ferrario, CM1
Ibdah, JA1
Huang, BS1
Xiao, J1
Shimada, M1
Liu, W1
Hu, D1
Matsumori, A1
Waanders, F1
Rienstra, H1
Boer, MW1
Zandvoort, A1
Rozing, J1
Navis, G1
van Goor, H1
Hillebrands, JL1
Takeda, Y1
Kamalov, G1
Deshmukh, PA1
Baburyan, NY1
Gandhi, MS1
Johnson, PL1
Ahokas, RA3
Bhattacharya, SK4
Sun, Y4
Gerling, IC3
Weber, KT5
van den Borne, SW1
Isobe, S1
Zandbergen, HR1
Li, P1
Petrov, A1
Wong, ND1
Fujimoto, S2
Fujimoto, A1
Lovhaug, D1
Smits, JF1
Daemen, MJ1
Blankesteijn, WM1
Reutelingsperger, C1
Narula, N1
Vannan, MA1
Pitt, B1
Hofstra, L1
Narula, J1
Stambler, BS1
Laurita, KR1
Shroff, SC1
Hoeker, G1
Martovitz, NL1
Tanaka, H1
Thanikachalam, PV1
Yamaguchi, K1
Tachikawa, H1
Kodama, M1
Aizawa, Y1
Bailey, MA1
Mullins, JJ1
Kenyon, CJ1
Sturgis, LC1
Cannon, JG1
Schreihofer, DA1
Brands, MW1
Tian, J1
Shidyak, A1
Periyasamy, SM1
Haller, S1
Taleb, M1
El-Okdi, N1
Elkareh, J1
Gupta, S1
Gohara, S1
Fedorova, OV1
Cooper, CJ1
Malhotra, D1
Bagrov, AY1
Shapiro, JI1
Luo, TY1
Liu, XH1
DU, X1
Liu, XP1
Lei, T1
Wang, HY1
Shi, JH1
Morimoto, T1
Takaya, T1
Kawamura, T1
Sunagawa, Y1
Wada, H1
Shimatsu, A1
Kita, T1
Hasegawa, K1
Zhao, J1
Li, J1
Li, Y1
Shan, H1
Gong, Y1
Yang, B1
Stein, M1
Boulaksil, M1
Jansen, JA1
Herold, E1
Noorman, M1
Joles, JA1
van Veen, TA1
Houtman, MJ1
Engelen, MA1
Hauer, RN1
de Bakker, JM1
van Rijen, HV1
Fukuda, A1
Iwatsubo, S1
Kawachi, H1
Kitamura, K2
Zhou, QX1
Mao, RR1
Duan, TT1
Tan, JW1
Tian, M1
Cao, J1
Xu, L1
Atalay, C1
Dogan, N1
Aykan, S1
Gundogdu, C1
Keles, MS1
Schyvens, CG1
Cole, TJ1
McKenzie, KU1
Vickers, JJ1
Whitworth, JA2
Laszlo, R1
Bentz, K1
Konior, A1
Eick, C1
Schreiner, B1
Kettering, K1
Schreieck, J1
Wesson, DE1
Simoni, J1
Schupp, N1
Queisser, N1
Gärtner, S1
Schmid, U1
Oli, RG1
Stopper, H1
Gu, X2
Peng, L2
Yang, D2
Ma, Q1
Zheng, Y2
Liu, C2
Zhu, B2
Song, L1
Sun, X2
Ma, Z2
Chimanji, NS1
Martin, CD1
Ganguly, R1
Stangland, JE1
Xu, Y1
Canan, BD1
Mays, TA1
Delfín, DA1
Martin-Fernandez, B1
Lahera, V1
Fortuno, MA1
Díez, J1
Zhou, X1
Crook, MF1
Sharif-Rodriguez, W1
Zhu, Y1
Ruben, Z1
Pan, Y1
Urosevic-Price, O1
Wang, L1
Flattery, AM1
Forrest, G1
Szeto, D1
Zhao, H1
Roy, S1
Forrest, MJ1
Brandt, CJ1
Kammer, D1
Fiebeler, A1
Klinge, U1
Iwazu, Y1
Muto, S1
Hirahara, I1
Fujisawa, G1
Takeda, S1
Kusano, E1
Maggio, N1
Segal, M1
Nariai, T1
Fujita, K1
Mori, M1
Katayama, S1
Hori, S1
Matsui, K1
Yoshida, S2
Takeuchi, M1
Ishizawa, K1
Noda, K1
Kobara, M1
Hamada, J1
Yoshifuji, Y1
Shiraishi, T1
Tanaka, T1
Wang, J1
Toba, H1
Nakata, T1
Luther, JM1
Luo, P1
Wang, Z1
Cohen, SE1
Kim, HS1
Fogo, AB2
Brown, NJ3
Goyal, BR1
Mehta, AA1
Sun, YE1
Bo, J1
Maron, BA1
Zhang, YY1
White, K1
Chan, SY1
Handy, DE1
Mahoney, CE1
Loscalzo, J1
Leopold, JA1
Zendaoui, A1
Lachance, D1
Roussel, E1
Couet, J1
Arsenault, M1
Ehsan, A1
McGraw, AP1
Aronovitz, MJ1
Galayda, C1
Conte, MS1
Karas, RH1
Rodríguez-Romo, R1
Reyna, J1
Nakano, M1
Hirooka, Y1
Matsukawa, R1
Ito, K1
Sunagawa, K1
Al-Mazroua, HA1
Al-Rasheed, NM1
Korashy, HM1
Frieler, RA1
Ray, JJ1
Meng, H1
Ramnarayanan, SP1
Usher, MG1
Su, EJ1
Berger, S1
Pinsky, DJ1
Lawrence, DA1
Wang, MM1
Mortensen, RM1
Lacolley, P1
Labat, C1
Pujol, A1
Delcayre, C2
Benetos, A1
Safar, M1
Suzuki, G1
Morita, H1
Mishima, T1
Sharov, VG1
Todor, A1
Tanhehco, EJ1
Rudolph, AE3
McMahon, EG3
Goldstein, S1
Sabbah, HN1
Qin, W1
Bond, BR1
Rocha, R2
Blomme, EA1
Goellner, JJ1
Funder, JW1
Biondi-Zoccai, GG1
Abbate, A1
Baldi, A1
Warrington, KJ1
Wodi, LA1
Herring, PA1
Lu, L1
Postlethwaite, AE1
Oestreicher, EM1
Martinez-Vasquez, D1
Stone, JR1
Jonasson, L1
Roubsanthisuk, W2
Mukasa, K1
Wang, D1
Liu, YH1
Yang, XP1
Rhaleb, NE1
Xu, J1
Peterson, E1
Carretero, OA1
Borowicz, KK1
Czuczwar, SJ1
Naruse, M1
Tanabe, A1
Hara, Y1
Takagi, S1
Imaki, T1
Takano, K1
Karram, T1
Abbasi, A1
Golomb, E1
Hochberg, I1
Winaver, J1
Hoffman, A1
Abassi, Z1
Law, PH1
Chhokar, VS1
Wakabayashi, K1
Sato, T1
Iso, Y1
Katagiri, T1
Takeyama, Y1
Tomita, K1
Aldigier, JC1
Kanjanbuch, T1
Ma, LJ1
Trune, DR2
Kempton, JB2
Gross, ND2
Edwards, HE1
Vimal, S1
Burnham, WM1
Bayorh, MA1
Mann, G1
Walton, M1
Eatman, D1
Celik, T1
Iyisoy, A1
Kursaklioglu, H1
Isik, E1
Gullulu, M1
Akdag, I1
Kahvecioglu, S1
Filiz, G1
Savci, V1
Shibata, S2
Nagase, T1
Gotoda, T2
Ramires, FJ1
Salemi, VM1
Ianni, BM1
Fernandes, F1
Martins, DG1
Billate, A1
Neto, EC1
Mady, C1
de Resende, MM1
Kriegel, AJ1
Greene, AS1
Yu, Y1
Kang, YM1
Zhang, ZH2
Wei, SG1
Chu, Y1
Weiss, RM2
Felder, RB2
Rigsby, CS1
Pollock, DM1
Dorrance, AM1
Iwanami, J1
Mogi, M1
Okamoto, S1
Gao, XY1
Li, JM1
Min, LJ1
Ide, A1
Tsukuda, K1
Iwai, M1
Horiuchi, M1
Nishioka, T1
Suzuki, M1
Onishi, K1
Takakura, N1
Inada, H1
Yoshida, T1
Hiroe, M1
Imanaka-Yoshida, K1
Thomas, M1
Vidal, A1
Török, J1
L'upták, I1
Matúsková, J1
Pechánová, O1
Zicha, J1
Kunes, J1
Simko, F1
Sartório, CL1
Fraccarollo, D2
Galuppo, P1
Leutke, M1
Ertl, G2
Stefanon, I1
Bauersachs, J2
Stankiewicz, A1
Gromotowicz, A1
Szemraj, J1
Wojewódzka-Zelezniakowicz, M1
Skrzypkowski, P1
Chabielska, E1
Takahashi, T2
Ono, H1
Ono, Y1
Ishimitsu, T1
Matsuoka, H1
McManus, F1
McInnes, GT1
Connell, JM1
Mashiko, S1
Ishihara, A1
Iwaasa, H1
Moriya, R1
Kitazawa, H1
Mitobe, Y1
Ito, J1
Gomori, A1
Matsushita, H1
MacNeil, DJ1
Van der Ploeg, LH1
Fukami, T1
Kanatani, A1
Nielsen, FT1
Jensen, BL1
Marcussen, N1
Skøtt, O1
Bie, P1
Schalekamp, MA1
Wenting, GJ1
Man in 't Veld, AJ1
Seki, T1
Toyomoto, T1
Morohashi, M1
Greene, EL1
Kren, S1
Hostetter, TH1
Wen, C1
Fraser, T1
Meirelles Pereira, LM1
Mandarim-de-Lacerda, CA1
Gretz, N1
Wehling, M1
Christ, M1
Laragh, JH1
Sealey, JE1
Parmley, WW1
Beck, L1
Blanc-Guillemaud, V1
Cherif, OK1
Jover, B1
Davy, JM1
Martinez, DV1
Matsumura, M1
Oestreicher, E1
Ochoa-Maya, M1
Williams, GH1
Beggah, AT1
Escoubet, B1
Puttini, S1
Cailmail, S1
Delage, V1
Ouvrard-Pascaud, A1
Bocchi, B1
Peuchmaur, M1
Farman, N1
Francis, J1
Mertin, J1
Simon, O1
Schmiedek, P1
Brilla, CG1
McClain, JM1
Zucker, IH1
Selye, H1
Haddow, JE1
Fish, CA1
Marshall, PC1
Lester, R1
Aspinall, RL1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319]Phase 12 participants (Actual)Interventional2018-12-05Terminated (stopped due to Inability to recruit participants.)
Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Citrus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA[NCT01681823]Phase 260 participants (Actual)Interventional2013-06-30Completed
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055]Phase 475 participants (Anticipated)Interventional2023-08-25Recruiting
Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients[NCT03314493]Phase 333 participants (Actual)Interventional2014-11-07Completed
Renal Ageing-sarcopenia Network: a Combined Genetic, Immunological and Psychological Approach to Dissect Frailty[NCT04630132]1,500 participants (Anticipated)Observational2017-03-25Recruiting
Pilot Non Randomised Controlled Trial of Short Term Spironolactone Use for Prevention of Acute Kidney Injury After Cardiac Surgery[NCT02417896]150 participants (Anticipated)Interventional2013-04-30Recruiting
Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720]Phase 2120 participants (Actual)Interventional2005-04-30Completed
Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial[NCT02948998]Phase 4260 participants (Anticipated)Interventional2018-05-14Not yet recruiting
Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658]Phase 390 participants (Anticipated)Interventional2017-08-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Efficacy: Change in Time to Complete a 100 Meter Timed Test.

The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months

Interventionsec (Number)
Spironolactone-0.6
Prednisolone-5.3

Efficacy: Dynamometry Score

Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months

,
Interventionkg (Number)
Elbow Flexion (Right)-BaselineElbow Flexion (Left)-BaselineElbow Extension (Right)-BaselineElbow Extension (Left)-BaselineKnee Flexion (Right)-BaselineKnee Flexion (Left)-BaselineKnee Extension (Right)-BaselineKnee Extension (Left)-BaselineElbow Flexion (Right)-Month 6Elbow Flexion (Left)-Month 6Elbow Extension (Right)-Month 6Elbow Extension (Left)-Month 6Knee Flexion (Right)-Month 6Knee Flexion (Left)-Month 6Knee Extension (Right)-Month 6Knee Extension (Left)-Month 6
Prednisolone3.64.15.34.13.33.44.85.22.93.44.33.84.13.965.1
Spironolactone00004.12.83.85.93.13.52.42.54.34.17.28.3

Safety Will be Monitored Through Regular Review of Electrolytes.

Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months

,
Interventionmmol/L (Number)
Sodium-BaselineSodium-Month 1Sodium-Month 2Sodium-Month 3Sodium-Month 4Sodium-Month 5Sodium-Month 6Potassium-BaselinePotassium-Month 1Potassium-Month 2Potassium-Month 3Potassium-Month 4Potassium-Month 5Potassium-Month 6Chloride-BaselineChloride-Month 1Chloride-Month 2Chloride-Month 3Chloride-Month 4Chloride-Month 5Chloride-Month 6CO2-BaselineCO2-Month 1CO2-Month 2CO2-Month 3CO2-Month 4CO2-Month 5CO2-Month 6
Prednisolone1401401391411391391433.844.53.94.64.23.910510510410510510610522242424252626
Spironolactone1421421411421391391404.54.74.24.14.54.54.310310910710310310310129222527282826

Reviews

7 reviews available for spironolactone and Disease Models, Animal

ArticleYear
Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2009, Volume: 32, Issue:5

    Topics: Aldosterone; Animals; Disease Models, Animal; Eplerenone; Humans; Hypertension; Mineralocorticoid Re

2009
Eplerenone, a new selective aldosterone blocker.
    Current pharmaceutical design, 2003, Volume: 9, Issue:13

    Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular System; Disease Model

2003
Eplerenone: cardiovascular protection.
    Circulation, 2003, May-20, Volume: 107, Issue:19

    Topics: Aldosterone; Animals; Cardiovascular Diseases; Cardiovascular System; Disease Models, Animal; Eplere

2003
[Roll of aldosterone in pathogenesis of kidney disorders].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2005, Jul-10, Volume: 94, Issue:7

    Topics: Aldosterone; Animals; Body Water; Disease Models, Animal; Eplerenone; Humans; Hypertension; Kidney D

2005
Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist.
    Nature clinical practice. Endocrinology & metabolism, 2008, Volume: 4, Issue:1

    Topics: Animals; Cardiovascular Diseases; Disease Models, Animal; Eplerenone; Heart Failure; Humans; Hyperte

2008
Pathogenesis of mineralocorticoid hypertension.
    Clinics in endocrinology and metabolism, 1981, Volume: 10, Issue:3

    Topics: Adenoma; Adrenal Gland Neoplasms; Adrenal Hyperplasia, Congenital; Adult; Aldosterone; Animals; Bloo

1981
K(+) depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion.
    Hypertension (Dallas, Tex. : 1979), 2001, Volume: 37, Issue:2 Pt 2

    Topics: Aldosterone; Animals; Antihypertensive Agents; Benzothiadiazines; Clinical Trials as Topic; Disease

2001

Trials

2 trials available for spironolactone and Disease Models, Animal

ArticleYear
Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.
    Journal of translational medicine, 2014, Dec-10, Volume: 12

    Topics: Angiotensinogen; Animals; Cytochrome P-450 CYP11B2; Disease Models, Animal; Double-Blind Method; Epl

2014
Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES.
    Circulation, 2000, Nov-07, Volume: 102, Issue:19

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Dose-Response Relationshi

2000

Other Studies

167 other studies available for spironolactone and Disease Models, Animal

ArticleYear
Myeloid Mineralocorticoid Receptor Transcriptionally Regulates P-Selectin Glycoprotein Ligand-1 and Promotes Monocyte Trafficking and Atherosclerosis.
    Arteriosclerosis, thrombosis, and vascular biology, 2021, Volume: 41, Issue:11

    Topics: Adult; Animals; Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Cell Adhesion; Disease Models, An

2021
Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model.
    Canadian journal of physiology and pharmacology, 2022, Sep-01, Volume: 100, Issue:9

    Topics: Animals; bcl-2-Associated X Protein; Disease Models, Animal; Female; Humans; Inflammasomes; Letrozol

2022
Myocardial global longitudinal strain: An early indicator of cardiac interstitial fibrosis modified by spironolactone, in a unique hypertensive rat model.
    PloS one, 2019, Volume: 14, Issue:8

    Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Echocardiography; Endomyocardial Fibrosis; Hype

2019
Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE/RAGE axis in a chronic renal failure rat model.
    BMC nephrology, 2019, 09-06, Volume: 20, Issue:1

    Topics: Animals; Cells, Cultured; Disease Models, Animal; Endothelium, Vascular; Humans; Kidney Failure, Chr

2019
Aldosterone Contributed to Pulmonary Arterial Hypertension Development via Stimulating Aquaporin Expression and Pulmonary Arterial Smooth Muscle Cells Proliferation.
    Pharmacology, 2020, Volume: 105, Issue:7-8

    Topics: Aldosterone; Animals; Aquaporin 1; beta Catenin; Cell Proliferation; Disease Models, Animal; Female;

2020
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
    Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:9

    Topics: Animals; Benzhydryl Compounds; Bisoprolol; Cardiovascular Agents; Chronic Disease; Disease Models, A

2020
Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat.
    Physiological reports, 2020, Volume: 8, Issue:10

    Topics: Aldosterone; Animals; Blood Pressure; Disease Models, Animal; Fibrosis; Hypertension; Kidney Disease

2020
Antidepressant effect in diabetes-associated depression: A novel potential of RAAS inhibition.
    Psychoneuroendocrinology, 2020, Volume: 118

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antidepressive Agents; Antihypertensive Agents; B

2020
Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS.
    Toxicology and applied pharmacology, 2021, 01-15, Volume: 411

    Topics: Adiponectin; Animals; Biomarkers; Disease Models, Animal; Female; Inflammation Mediators; Letrozole;

2021
Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists.
    Journal of endocrinological investigation, 2022, Volume: 45, Issue:1

    Topics: Adipose Tissue, Brown; Animals; Disease Models, Animal; Gene Expression Profiling; Insulin Resistanc

2022
Comparative evaluation of torasemide and spironolactone on adverse cardiac remodeling in a rat model of dilated cardiomyopathy.
    Cardiovascular therapeutics, 2017, Volume: 35, Issue:5

    Topics: Animals; Autoimmunity; Biomarkers; Cardiac Myosins; Cardiomyopathy, Dilated; Disease Models, Animal;

2017
Spironolactone is an antagonist of NRG1-ERBB4 signaling and schizophrenia-relevant endophenotypes in mice.
    EMBO molecular medicine, 2017, Volume: 9, Issue:10

    Topics: Animals; Behavior Rating Scale; Cell Line, Tumor; Coculture Techniques; Disease Models, Animal; Huma

2017
Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs.
    Basic research in cardiology, 2017, Volume: 112, Issue:5

    Topics: Animals; Calcium Signaling; Cells, Cultured; Coronary Artery Disease; Coronary Vessels; Disease Mode

2017
Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload.
    Scientific reports, 2017, 09-12, Volume: 7, Issue:1

    Topics: Aldosterone; Animals; Biomarkers; Blood Pressure; Cardiomegaly; Disease Models, Animal; Disease Susc

2017
Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling.
    Cardiovascular research, 2018, 01-01, Volume: 114, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; DNA Helicases; DNA-Binding Proteins; Endo

2018
Mineralocorticoid receptor antagonism protects the aorta from vascular smooth muscle cell proliferation and collagen deposition in a rat model of adrenal aldosterone-producing adenoma.
    Journal of physiology and biochemistry, 2018, Volume: 74, Issue:1

    Topics: ACTH-Secreting Pituitary Adenoma; Aldosterone; Animals; Antihypertensive Agents; Aorta; Cell Prolife

2018
Aldosterone is involved in the pathogenesis of obesity-related glomerulopathy through activation of Wnt/β-catenin signaling in podocytes.
    Molecular medicine reports, 2018, Volume: 17, Issue:3

    Topics: Aldosterone; Animals; beta Catenin; Disease Models, Animal; Down-Regulation; Eplerenone; Glomerulone

2018
Topical Administration of Spironolactone-Loaded Nanomicelles Prevents Glucocorticoid-Induced Delayed Corneal Wound Healing in Rabbits.
    Molecular pharmaceutics, 2018, 03-05, Volume: 15, Issue:3

    Topics: Administration, Ophthalmic; Animals; Canrenoic Acid; Cornea; Corneal Injuries; Disease Models, Anima

2018
Mineralocorticoid receptor antagonism reverses diabetes-related coronary vasodilator dysfunction: A unique vascular transcriptomic signature.
    Pharmacological research, 2018, Volume: 134

    Topics: Animals; Arterioles; Coronary Artery Disease; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic

2018
[Analysis of the mitochondrial function and ultrastructure in healthy albino mice treated with heart failure medications]
    Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina), 2017, 09-08, Volume: 74, Issue:3

    Topics: Animals; Antihypertensive Agents; Atenolol; Cardiotonic Agents; Digoxin; Disease Models, Animal; Diu

2017
Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019, 05-01, Volume: 34, Issue:5

    Topics: Acute Kidney Injury; Animals; Delayed-Action Preparations; Disease Models, Animal; Disease Progressi

2019
Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes.
    International urology and nephrology, 2019, Volume: 51, Issue:4

    Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme 2; Animals; Autophagy; Beclin-1; Diabetes Me

2019
Mineralocorticoid receptor antagonists improve membrane integrity independent of muscle force in muscular dystrophy.
    Human molecular genetics, 2019, 06-15, Volume: 28, Issue:12

    Topics: Animals; Cell Membrane; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Mineralo

2019
Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension.
    Hypertension (Dallas, Tex. : 1979), 2013, Volume: 61, Issue:5

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds

2013
The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:9

    Topics: Adrenalectomy; Aldosterone; Animals; Blood Glucose; Blood Pressure; Cells, Cultured; Cholesterol; Di

2013
Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism.
    Nagoya journal of medical science, 2013, Volume: 75, Issue:1-2

    Topics: Animals; Atrophy; Blood Pressure; Corticosterone; Disease Models, Animal; Fibrosis; Heart Diseases;

2013
Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt.
    Arteriosclerosis, thrombosis, and vascular biology, 2013, Volume: 33, Issue:7

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim

2013
Protective effects of selective mineralocorticoid receptor antagonist against aortic aneurysm progression in a novel murine model.
    The Journal of surgical research, 2013, Volume: 185, Issue:1

    Topics: Animals; Aortic Aneurysm; Blood Pressure; Chemokine CCL2; Disease Models, Animal; Disease Progressio

2013
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2014, Volume: 36, Issue:5

    Topics: Animals; Animals, Newborn; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Disease

2014
A cornerstone of heart failure treatment is not effective in experimental right ventricular failure.
    International journal of cardiology, 2013, Nov-05, Volume: 169, Issue:3

    Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Eplerenone; Heart Failure; Losartan; Mal

2013
Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes.
    Cardiovascular diabetology, 2013, Nov-21, Volume: 12

    Topics: Animals; Apoptosis; Cardiomegaly; Cell Line; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; D

2013
Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress.
    Kidney & blood pressure research, 2013, Volume: 37, Issue:6

    Topics: Animals; Cell Proliferation; Disease Models, Animal; Eplerenone; Fibrosis; Inflammation; Male; Miner

2013
Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
    Hypertension (Dallas, Tex. : 1979), 2014, Volume: 63, Issue:4

    Topics: Animals; Antibodies; Desoxycorticosterone Acetate; Disease Models, Animal; Down-Regulation; Forkhead

2014
The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation.
    The Journal of biological chemistry, 2014, Mar-07, Volume: 289, Issue:10

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Atrial Fibrillation; Connective Tissue Growth

2014
Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Diuretics; Dystrophin; Female; Gene Expression;

2014
Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure.
    Journal of cardiovascular electrophysiology, 2014, Volume: 25, Issue:5

    Topics: Action Potentials; Animals; Anti-Inflammatory Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artifici

2014
Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
    Journal of cardiovascular pharmacology, 2014, Volume: 64, Issue:1

    Topics: Animals; Autoradiography; Cardiomegaly; Disease Models, Animal; Eplerenone; Heart Failure; Kidney Di

2014
Angiogenesis inhibition impairs testicular morphology in experimental left varicocele rat model.
    Actas urologicas espanolas, 2014, Volume: 38, Issue:7

    Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Male; Random Allocation; Rats; Rats, Wista

2014
Blocking the mineralocorticoid receptor improves effectiveness of steroid treatment for low back pain in rats.
    Anesthesiology, 2014, Volume: 121, Issue:3

    Topics: Androstadienes; Animals; Disease Models, Animal; Eplerenone; Fluticasone; Ganglia, Spinal; Inflammat

2014
The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis.
    Laboratory investigation; a journal of technical methods and pathology, 2014, Volume: 94, Issue:8

    Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Cilazapril

2014
Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.
    Circulation. Heart failure, 2014, Volume: 7, Issue:5

    Topics: Animals; Atrial Natriuretic Factor; Blotting, Western; Cardiomyopathy, Dilated; Connective Tissue Gr

2014
Cardiac macrophages and apoptosis after myocardial infarction: effects of central MR blockade.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2014, Oct-01, Volume: 307, Issue:7

    Topics: Aldosterone; Animals; Apoptosis; Caspase 3; Disease Models, Animal; Eplerenone; Macrophages; Male; M

2014
Glucocorticoids activate cardiac mineralocorticoid receptors in adrenalectomized Dahl salt-sensitive rats.
    Nagoya journal of medical science, 2014, Volume: 76, Issue:1-2

    Topics: Adrenalectomy; Animals; Blood Pressure; Collagen Type I; Collagen Type III; Corticosterone; Disease

2014
Spironolactone decreases the somatic signs of opiate withdrawal by blocking the mineralocorticoid receptors (MR).
    Toxicology, 2014, Dec-04, Volume: 326

    Topics: Analgesics, Opioid; Animals; Disease Models, Animal; Enzyme Activation; Hypothalamo-Hypophyseal Syst

2014
The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.
    JACC. Heart failure, 2015, Volume: 3, Issue:1

    Topics: Acute Kidney Injury; Aldosterone; Animals; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay

2015
Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2015, Volume: 16, Issue:2

    Topics: Adrenalectomy; Aldosterone; Animals; Chronic Disease; Cyclosporine; Cytochrome P-450 CYP11B2; Diseas

2015
Aldosterone Contributes to Sympathoexcitation in Renovascular Hypertension.
    American journal of hypertension, 2015, Volume: 28, Issue:9

    Topics: Actins; Aldosterone; Animals; Antihypertensive Agents; Arterial Pressure; Baroreflex; Disease Models

2015
Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:9

    Topics: Animals; Biomarkers; Disease Models, Animal; Eplerenone; Liver; Liver Cirrhosis; Male; Mice; Mice, I

2015
Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease.
    Clinical and experimental pharmacology & physiology, 2015, Volume: 42, Issue:4

    Topics: Animals; Aorta; Biomarkers; Blood Pressure; Cytoprotection; Disease Models, Animal; Disease Progress

2015
Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction.
    Hypertension (Dallas, Tex. : 1979), 2015, Volume: 65, Issue:5

    Topics: Animals; Diastole; Disease Models, Animal; Echocardiography; Heart Ventricles; Mineralocorticoid Rec

2015
Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice.
    American journal of physiology. Heart and circulatory physiology, 2015, May-01, Volume: 308, Issue:9

    Topics: Animals; Cardiomegaly; Diastole; Diet, High-Fat; Diet, Western; Dietary Sucrose; Disease Models, Ani

2015
Involvement of renin-angiotensin-aldosterone system in calcium oxalate crystal induced activation of NADPH oxidase and renal cell injury.
    World journal of urology, 2016, Volume: 34, Issue:1

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Angiotensinogen; Animals; Calcium Oxalate; Cell Line; C

2016
Spironolactone Regulates HCN Protein Expression Through Micro-RNA-1 in Rats With Myocardial Infarction.
    Journal of cardiovascular pharmacology, 2015, Volume: 65, Issue:6

    Topics: Animals; Arrhythmias, Cardiac; Disease Models, Animal; Gene Expression Regulation; Hyperpolarization

2015
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    European journal of pharmacology, 2015, Aug-15, Volume: 761

    Topics: Administration, Oral; Adrenalectomy; Aldosterone; Animals; Antihypertensive Agents; Binding, Competi

2015
Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.
    Clinical and experimental pharmacology & physiology, 2015, Volume: 42, Issue:11

    Topics: Adrenal Glands; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biomark

2015
Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension.
    Hypertension (Dallas, Tex. : 1979), 2015, Volume: 66, Issue:4

    Topics: Animals; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Galectin 3; Humans; Hyperal

2015
Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification.
    American journal of physiology. Renal physiology, 2015, Dec-01, Volume: 309, Issue:11

    Topics: Adenine; Animals; Aorta, Abdominal; Aortic Diseases; Apoptosis; Biomarkers; Disease Models, Animal;

2015
Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload-Induced Cardiac Injury.
    Hypertension (Dallas, Tex. : 1979), 2016, Volume: 67, Issue:1

    Topics: Animals; Disease Models, Animal; Eplerenone; Heart Failure; Male; Mice; Mice, Inbred C57BL; Mineralo

2016
Treadmill exercise ameliorates ischemia-induced brain edema while suppressing Na⁺/H⁺ exchanger 1 expression.
    Experimental neurology, 2016, Volume: 277

    Topics: Acid Sensing Ion Channel Blockers; Animals; Aquaporin 4; Brain Edema; Cells, Cultured; Corticosteron

2016
Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy.
    Journal of cardiovascular pharmacology, 2016, Volume: 67, Issue:5

    Topics: Animals; Cardiomegaly; Disease Models, Animal; Eplerenone; Gene Expression; Male; Mice; Mice, Inbred

2016
Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats.
    Cardiovascular therapeutics, 2016, Volume: 34, Issue:4

    Topics: Action Potentials; Animals; Apoptosis; Cardiotonic Agents; Cardiotoxicity; Collagen; Cytoprotection;

2016
A novel role for the mineralocorticoid receptor in glucocorticoid driven vascular calcification.
    Vascular pharmacology, 2016, Volume: 86

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apoptosis; Corticosterone; Disease Models, Ani

2016
Do Diuretics have Antinociceptive Actions: Studies of Spironolactone, Eplerenone, Furosemide and Chlorothiazide, Individually and with Oxycodone and Morphine.
    Basic & clinical pharmacology & toxicology, 2017, Volume: 120, Issue:1

    Topics: Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Brain; Chlorothiazide; Disease Models, An

2017
Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by β-Adrenergic Overstimulation: Role of Perivascular Adipose Tissue.
    Hypertension (Dallas, Tex. : 1979), 2016, Volume: 68, Issue:3

    Topics: Adipose Tissue; Analysis of Variance; Animals; Cardiomegaly; Disease Models, Animal; Isoproterenol;

2016
(Pro)Renin receptor regulates potassium homeostasis through a local mechanism.
    American journal of physiology. Renal physiology, 2017, 09-01, Volume: 313, Issue:3

    Topics: Adrenalectomy; Aldosterone; Animals; Cytochrome P-450 CYP11B2; Disease Models, Animal; Epithelial So

2017
Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats.
    Endocrinology, 2016, Volume: 157, Issue:10

    Topics: Adrenal Glands; Aldosterone; Animals; Blood Glucose; Body Weight; Cytochrome P-450 CYP11B2; Diabetes

2016
Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice.
    Journal of neuromuscular diseases, 2016, Volume: 3, Issue:3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Eplerenone; Gene Knockdow

2016
Sexual Reassignment Fails to Prevent Kennedy's Disease.
    Journal of neuromuscular diseases, 2016, 03-03, Volume: 3, Issue:1

    Topics: Androgen Antagonists; Animals; Bulbo-Spinal Atrophy, X-Linked; Disease Models, Animal; Drosophila; F

2016
Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:11

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Dise

2008
Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions.
    Journal of hypertension, 2008, Volume: 26, Issue:7

    Topics: Angiotensin II; Animals; Antioxidants; Cyclic N-Oxides; Diastole; Disease Models, Animal; Eplerenone

2008
The effect of aldosterone antagonist in experimental nephropathy induced by cyclosporine A.
    Renal failure, 2008, Volume: 30, Issue:4

    Topics: Animals; Creatinine; Cyclosporine; Disease Models, Animal; Disease Progression; Glomerular Filtratio

2008
Cardiac benefits of mineralocorticoid receptor inhibition in renal failure.
    Hypertension (Dallas, Tex. : 1979), 2008, Volume: 52, Issue:2

    Topics: Aldosterone; Animals; Cohort Studies; Disease Models, Animal; Humans; Hypertrophy, Left Ventricular;

2008
Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats.
    Hypertension (Dallas, Tex. : 1979), 2008, Volume: 52, Issue:2

    Topics: Analysis of Variance; Animals; Biomarkers; Blotting, Western; Cardiomegaly; Disease Models, Animal;

2008
Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder.
    Hypertension (Dallas, Tex. : 1979), 2008, Volume: 52, Issue:2

    Topics: Aldosterone; Animals; Blood Pressure Determination; Disease Models, Animal; Echocardiography, Dopple

2008
Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart.
    Circulation research, 2009, Feb-13, Volume: 104, Issue:3

    Topics: Animals; Cardiomegaly; Connexin 43; Disease Models, Animal; Diuretics; Gap Junctions; Heart Conducti

2009
Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation.
    Hypertension (Dallas, Tex. : 1979), 2009, Volume: 53, Issue:2

    Topics: Aldosterone; Animals; Aorta, Thoracic; Apoptosis; bcl-Associated Death Protein; Blood Pressure; Cyto

2009
Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2009, Volume: 296, Issue:4

    Topics: Aldosterone; Animals; Blood Pressure; Corticosterone; Cytochrome P-450 CYP11B2; Disease Models, Anim

2009
Anti-inflammatory effects of eplerenone on viral myocarditis.
    European journal of heart failure, 2009, Volume: 11, Issue:4

    Topics: Animals; Cardiovirus Infections; Disease Models, Animal; DNA, Viral; Encephalomyocarditis virus; Epl

2009
Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats.
    American journal of physiology. Renal physiology, 2009, Volume: 296, Issue:5

    Topics: Animals; Blood Pressure; Body Weight; Chronic Disease; Creatinine; Delayed Graft Function; Disease M

2009
Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism.
    Journal of cardiovascular pharmacology, 2009, Volume: 53, Issue:5

    Topics: Aldehydes; Aldosterone; Amlodipine; Animals; Calcium; Calcium Channel Blockers; Chronic Disease; Dis

2009
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.
    JACC. Cardiovascular imaging, 2009, Volume: 2, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopri

2009
Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure.
    Heart rhythm, 2009, Volume: 6, Issue:6

    Topics: Animals; Disease Models, Animal; Dogs; Electrocardiography; Eplerenone; Heart Failure; Mineralocorti

2009
[Effects of various diuretics on cardiac function in rats with heart failure].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2009, Volume: 129, Issue:7

    Topics: Animals; Cytochrome P-450 CYP11B2; Disease Models, Animal; Diuretics; Furosemide; Heart Failure; Hem

2009
Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of Cushing syndrome.
    Hypertension (Dallas, Tex. : 1979), 2009, Volume: 54, Issue:4

    Topics: Adrenocorticotropic Hormone; Animals; Blood Pressure; Cushing Syndrome; Disease Models, Animal; Epit

2009
The role of aldosterone in mediating the dependence of angiotensin hypertension on IL-6.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2009, Volume: 297, Issue:6

    Topics: Aldosterone; Angiotensins; Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; D

2009
Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.
    Hypertension (Dallas, Tex. : 1979), 2009, Volume: 54, Issue:6

    Topics: Animals; Bufanolides; Canrenone; Cardiomyopathies; Cardiotonic Agents; Cells, Cultured; Disease Mode

2009
[Effects of perindopril and spirolactone on plasma aldosterone and left atrial remodeling in a canine model of atrial fibrillation].
    Zhonghua xin xue guan bing za zhi, 2009, Volume: 37, Issue:7

    Topics: Aldosterone; Animals; Atrial Fibrillation; Atrial Function; Disease Models, Animal; Dogs; Male; Mine

2009
Aldosterone signaling associates with p300/GATA4 transcriptional pathway during the hypertrophic response of cardiomyocytes.
    Circulation journal : official journal of the Japanese Circulation Society, 2010, Volume: 74, Issue:1

    Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Chlorocebus aethiops; COS Cells; Disease Models, An

2010
Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing.
    British journal of pharmacology, 2010, Volume: 159, Issue:8

    Topics: Animals; Atrial Fibrillation; Blotting, Western; Disease Models, Animal; Dogs; Female; Heart Atria;

2010
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model.
    American journal of physiology. Heart and circulatory physiology, 2010, Volume: 299, Issue:2

    Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pr

2010
Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
    Nephrology (Carlton, Vic.), 2010, Volume: 15, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Disease Models, Animal; Eplerenone

2010
Stress within the postseizure time window inhibits seizure recurrence.
    Epilepsy & behavior : E&B, 2010, Volume: 18, Issue:3

    Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents; Anticonvulsants; Circadian Rhythm; Corticos

2010
The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats.
    Singapore medical journal, 2010, Volume: 51, Issue:6

    Topics: Acute Lung Injury; Animals; Blood Gas Analysis; Disease Models, Animal; Lung; Male; Mineralocorticoi

2010
The glucocorticoid receptor is required for experimental adrenocorticotrophic hormone-induced hypertension in mice.
    Clinical and experimental pharmacology & physiology, 2010, Volume: 37, Issue:11

    Topics: Adrenocorticotropic Hormone; Animals; Blood Pressure; Body Weight; Disease Models, Animal; Heart Rat

2010
Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits.
    Naunyn-Schmiedeberg's archives of pharmacology, 2010, Volume: 382, Issue:4

    Topics: Animals; Atrial Fibrillation; Calcium Channels, L-Type; Cardiac Pacing, Artificial; Disease Models,

2010
Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet.
    Kidney international, 2010, Volume: 78, Issue:11

    Topics: Acid-Base Equilibrium; Acidosis; Administration, Oral; Aldosterone; Animals; Bicarbonates; Calcium G

2010
Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2011, Volume: 25, Issue:3

    Topics: Animals; Apoptosis; Blood Pressure; Cell Division; Desoxycorticosterone; Disease Models, Animal; DNA

2011
The respective and interaction effects of spinal GRs and MRs on radicular pain induced by chronic compression of the dorsal root ganglion in the rat.
    Brain research, 2011, Jun-17, Volume: 1396

    Topics: Animals; Dexamethasone; Disease Models, Animal; Drug Synergism; Ganglia, Spinal; Hormone Antagonists

2011
Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Animals; Cardiac Imaging Techniques; Cardiomyopathies; Cardiotonic Agents; Disease Models, Animal; D

2011
A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone.
    American journal of physiology. Heart and circulatory physiology, 2011, Volume: 301, Issue:6

    Topics: Aldosterone; Animals; Blood Pressure; Blotting, Western; Collagen; Cytokines; Disease Models, Animal

2011
Chronic antagonism of the mineralocorticoid receptor ameliorates hypertension and end organ damage in a rodent model of salt-sensitive hypertension.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2011, Volume: 33, Issue:8

    Topics: Aldosterone; Animals; Blood Pressure; Chronic Disease; Creatinine; Disease Models, Animal; Disease P

2011
Beneficial effects of hydrocortisone or spironolactone coating on foreign body response to mesh biomaterial in a mouse model.
    Journal of biomedical materials research. Part A, 2011, Dec-01, Volume: 99, Issue:3

    Topics: Animals; Coated Materials, Biocompatible; Collagen; Disease Models, Animal; Foreign-Body Reaction; G

2011
Matrix metalloproteinase 2 induces epithelial-mesenchymal transition in proximal tubules from the luminal side and progresses fibrosis in mineralocorticoid/salt-induced hypertensive rats.
    Journal of hypertension, 2011, Volume: 29, Issue:12

    Topics: Animals; Collagen; Desoxycorticosterone; Disease Models, Animal; Disease Progression; Drug Therapy,

2011
Stress and corticosteroid modulation of seizures and synaptic inhibition in the hippocampus.
    Experimental neurology, 2012, Volume: 234, Issue:1

    Topics: Adrenal Cortex Hormones; Aldosterone; Animals; Biophysics; Disease Models, Animal; Drug Interactions

2012
Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats.
    Pharmacology, 2012, Volume: 89, Issue:1-2

    Topics: Acetylglucosaminidase; Aldosterone; Animals; Antihypertensive Agents; Benzoxazines; Biomarkers; Bloo

2012
Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation.
    Journal of the American Society of Nephrology : JASN, 2012, Volume: 23, Issue:6

    Topics: Acute Kidney Injury; Adrenalectomy; Aldosterone; Analysis of Variance; Angiotensin II; Animals; Blot

2012
Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
    Journal of cardiovascular pharmacology, 2012, Volume: 60, Issue:2

    Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cel

2012
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
    Kidney international, 2012, Volume: 82, Issue:6

    Topics: Aldosterone; Angiotensin II; Animals; Aorta; Biomarkers; Blood Pressure; Cytochrome P-450 CYP11B2; D

2012
Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy.
    Acta cardiologica, 2012, Volume: 67, Issue:2

    Topics: Adrenergic beta-Agonists; Algorithms; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazol

2012
Intrathecal injection of spironolactone attenuates radicular pain by inhibition of spinal microglia activation in a rat model.
    PloS one, 2012, Volume: 7, Issue:6

    Topics: Animals; Blotting, Western; Cytokines; Disease Models, Animal; Ganglia, Spinal; Immunohistochemistry

2012
Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.
    Circulation, 2012, Aug-21, Volume: 126, Issue:8

    Topics: Aldosterone; Animals; Cells, Cultured; Cysteine; Disease Models, Animal; Endothelial Cells; Endothel

2012
Effects of spironolactone treatment on an experimental model of chronic aortic valve regurgitation.
    The Journal of heart valve disease, 2012, Volume: 21, Issue:4

    Topics: Animals; Aortic Valve Insufficiency; Blood Pressure; Cardiomegaly; Chronic Disease; Diastole; Diseas

2012
Mineralocorticoid receptor antagonism inhibits vein graft remodeling in mice.
    The Journal of thoracic and cardiovascular surgery, 2013, Volume: 145, Issue:6

    Topics: Aldosterone; Analysis of Variance; Animals; Aorta; Disease Models, Animal; Gene Expression; Graft Re

2013
Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury.
    Kidney international, 2013, Volume: 83, Issue:1

    Topics: Acute Kidney Injury; Animals; Collagen Type I; Disease Models, Animal; Diuretics; Dose-Response Rela

2013
Mineralocorticoid receptors/epithelial Na(+) channels in the choroid plexus are involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:3

    Topics: Animals; Blood Pressure; Choroid Plexus; Disease Models, Animal; Epithelial Sodium Channels; Epleren

2013
Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice.
    Journal of cardiovascular pharmacology, 2012, Volume: 60, Issue:6

    Topics: Animals; Aorta, Thoracic; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Cytochrome P-450 CYP1

2012
Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.
    Journal of cardiovascular pharmacology, 2013, Volume: 61, Issue:4

    Topics: Animals; Blotting, Western; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytokines; Disease Models,

2013
Myeloid mineralocorticoid receptor during experimental ischemic stroke: effects of model and sex.
    Journal of the American Heart Association, 2012, Volume: 1, Issue:5

    Topics: Animals; Brain Ischemia; Disease Models, Animal; Eplerenone; Female; Gene Expression Profiling; Immu

2012
Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone.
    Circulation, 2002, Nov-26, Volume: 106, Issue:22

    Topics: Aldosterone; Animals; Blood Pressure; Blotting, Northern; Carotid Arteries; Collagen; Collagen Type

2002
Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Circulation, 2002, Dec-03, Volume: 106, Issue:23

    Topics: Administration, Oral; Animals; Chronic Disease; Disease Models, Animal; Disease Progression; Dogs; E

2002
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.
    Circulation research, 2003, Jul-11, Volume: 93, Issue:1

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Dis

2003
Potential antiapoptotic activity of aldosterone antagonists in postinfarction remodeling.
    Circulation, 2003, Jul-29, Volume: 108, Issue:4

    Topics: Animals; Apoptosis; Disease Models, Animal; Dogs; Mineralocorticoid Receptor Antagonists; Myocardial

2003
Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface.
    Circulation research, 2003, Nov-14, Volume: 93, Issue:10

    Topics: Aldosterone; Animals; Calcium; Cell Separation; Coronary Vessels; Disease Models, Animal; Disease Pr

2003
Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.
    Circulation, 2003, Nov-18, Volume: 108, Issue:20

    Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Coronary Artery Disease; Disease Mode

2003
Role of a selective aldosterone blocker in mice with chronic heart failure.
    Journal of cardiac failure, 2004, Volume: 10, Issue:1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output; Collagen; Disease Models, Animal;

2004
Aminoglutethimide but not spironolactone enhances the anticonvulsant effect of some antiepileptics against amygdala-kindled seizures in rats.
    Journal of neural transmission (Vienna, Austria : 1996), 2005, Volume: 112, Issue:7

    Topics: Adrenergic Agents; Aminoglutethimide; Amygdala; Animals; Anticonvulsants; Clonazepam; Disease Models

2005
Effects of AT1 receptor antagonist and spironolactone on cardiac expression of ET-1 mRNA in SHR-SP/Izm.
    Journal of cardiovascular pharmacology, 2004, Volume: 44 Suppl 1

    Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Ben

2004
Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
    American journal of physiology. Heart and circulatory physiology, 2005, Volume: 289, Issue:4

    Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Arteri

2005
Diuretics and bone loss in rats with aldosteronism.
    Journal of the American College of Cardiology, 2005, Jul-05, Volume: 46, Issue:1

    Topics: Animals; Bone Density; Calcium; Disease Models, Animal; Diuretics; Furosemide; Hyperaldosteronism; M

2005
Eplerenone suppresses neointimal formation after coronary stent implantation in swine.
    International journal of cardiology, 2006, Feb-15, Volume: 107, Issue:2

    Topics: Actins; Administration, Oral; Animals; Blood Vessel Prosthesis Implantation; Collagen Type I; Collag

2006
Regression of existing glomerulosclerosis by inhibition of aldosterone.
    Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:11

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Diuretics; Glomerulonephri

2005
Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear.
    Hearing research, 2006, Volume: 212, Issue:1-2

    Topics: Aldosterone; Animals; Antigen-Antibody Complex; Auditory Threshold; Autoimmune Diseases; Body Weight

2006
The acute anticonvulsant effects of deoxycorticosterone in developing rats: role of metabolites and mineralocorticoid-receptor responses.
    Epilepsia, 2005, Volume: 46, Issue:12

    Topics: Animals; Animals, Newborn; Anticonvulsants; Desoxycorticosterone; Disease Models, Animal; Enzyme Inh

2005
Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2006, Volume: 28, Issue:2

    Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Blood

2006
Eplerenone suppresses neointima after coronary stenting in pigs: could it be extrapolated to stent restenosis in humans?
    International journal of cardiology, 2007, Jan-31, Volume: 115, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Animals; Collagen; Coronary Restenosis; Disease Models, Animal; Eple

2007
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
    Renal failure, 2006, Volume: 28, Issue:6

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Prolife

2006
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors.
    Journal of the American Society of Nephrology : JASN, 2006, Volume: 17, Issue:12

    Topics: Adipocytes; Adrenal Glands; Aldosterone; Animals; Cyclic N-Oxides; Disease Models, Animal; Eplerenon

2006
Aldosterone antagonism in an inflammatory state: evidence for myocardial protection.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2006, Volume: 7, Issue:3

    Topics: Aldosterone; Animals; Cardiotonic Agents; Chagas Cardiomyopathy; Collagen; Cricetinae; Disease Model

2006
Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy.
    Journal of cardiovascular pharmacology, 2006, Volume: 48, Issue:6

    Topics: Administration, Oral; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals

2006
Increased cyclooxygenase-2 expression in hypothalamic paraventricular nucleus in rats with heart failure: role of nuclear factor kappaB.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cyclooxygenase 2; Cytokines; Disease Models, Animal

2007
Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats.
    Microvascular research, 2007, Volume: 73, Issue:3

    Topics: Animals; Blood Pressure; Cerebrovascular Circulation; Compliance; Disease Models, Animal; Dose-Respo

2007
Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model.
    European journal of pharmacology, 2007, Jul-02, Volume: 566, Issue:1-3

    Topics: Animals; Blood Pressure; Brain Ischemia; Disease Models, Animal; Eplerenone; Infarction, Middle Cere

2007
Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation.
    Journal of cardiovascular pharmacology, 2007, Volume: 49, Issue:5

    Topics: Aldosterone; Analysis of Variance; Angiotensin II; Animals; Blood Pressure; Body Weight; Cytokines;

2007
Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone.
    American journal of physiology. Heart and circulatory physiology, 2007, Volume: 293, Issue:4

    Topics: Aldosterone; Animals; Coronary Vessels; Disease Models, Animal; Feces; Fibrosis; Homeostasis; Hypera

2007
Comparison of the effect of simvastatin, spironolactone and L-arginine on endothelial function of aorta in hereditary hypertriglyceridemic rats.
    Physiological research, 2007, Volume: 56 Suppl 2

    Topics: Acetylcholine; Animals; Aorta; Arginine; Blood Pressure; Disease Models, Animal; Dose-Response Relat

2007
Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 50, Issue:5

    Topics: Animals; Aorta, Thoracic; Disease Models, Animal; Dose-Response Relationship, Drug; Eplerenone; Male

2007
Acute aldosterone infusion enhances thrombosis development in normotensive rats.
    Thrombosis and haemostasis, 2007, Volume: 98, Issue:3

    Topics: Aldosterone; Animals; Blood Coagulation; Blood Pressure; Carboxypeptidase B2; Disease Models, Animal

2007
Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 50, Issue:5

    Topics: Aldosterone; Animals; Antioxidants; Cyclic N-Oxides; Disease Models, Animal; Eplerenone; Hypertensio

2007
Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1).
    International heart journal, 2007, Volume: 48, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Disease Models, Animal;

2007
Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine.
    Obesity (Silver Spring, Md.), 2008, Volume: 16, Issue:7

    Topics: Adiposity; Animals; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Weight; Caloric R

2008
Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:9

    Topics: Animals; Blood Pressure; Cyclosporine; Disease Models, Animal; Eplerenone; Glomerular Filtration Rat

2008
Effects of topically applied spironolactone on androgen stimulated sebaceous glands in the hamster pinna.
    The Journal of dermatology, 1995, Volume: 22, Issue:4

    Topics: Administration, Topical; Animals; Cricetinae; Disease Models, Animal; Female; Mesocricetus; Sebaceou

1995
Role of aldosterone in the remnant kidney model in the rat.
    The Journal of clinical investigation, 1996, Aug-15, Volume: 98, Issue:4

    Topics: Adrenal Glands; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biph

1996
Adrenocorticotrophin-induced hypertension: effects of mineralocorticoid and glucocorticoid receptor antagonism.
    Journal of hypertension, 1999, Volume: 17, Issue:3

    Topics: Adrenocorticotropic Hormone; Animals; Anti-Bacterial Agents; Blood Pressure; Disease Models, Animal;

1999
Effect of antihypertensive drugs on the myocardial microvessels in rats with nitric oxide blockade.
    Pathology, research and practice, 2000, Volume: 196, Issue:5

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Capillaries; Coronary Circulation; Coronary Vessel

2000
How many medicines do patients with heart failure need?
    Circulation, 2001, Mar-27, Volume: 103, Issue:12

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit

2001
Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction.
    Cardiology, 2001, Volume: 96, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; Chronic Disease; Disease Mo

2001
Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading.
    Hypertension (Dallas, Tex. : 1979), 2002, Volume: 39, Issue:2 Pt 2

    Topics: Aldosterone; Angiotensin II; Animals; Diet, Sodium-Restricted; Disease Models, Animal; Eplerenone; H

2002
Spironolactone blocks glucocorticoid-mediated hearing preservation in autoimmune mice.
    The Laryngoscope, 2002, Volume: 112, Issue:2

    Topics: Aldosterone; Animals; Audiometry, Pure-Tone; Auditory Threshold; Disease Models, Animal; Drug Intera

2002
Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes.
    Proceedings of the National Academy of Sciences of the United States of America, 2002, May-14, Volume: 99, Issue:10

    Topics: Animals; Base Sequence; Disease Models, Animal; DNA, Complementary; Fibrosis; Gene Expression; Heart

2002
The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure.
    American journal of physiology. Heart and circulatory physiology, 2002, Volume: 283, Issue:1

    Topics: Action Potentials; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Capto

2002
The influence of aldosterone and anticonvulsant drugs on electroencephalographic and clinical disturbances induced by the spirolactone derivative, potassium canrenoate.
    Journal of the neurological sciences, 1975, Volume: 24, Issue:1

    Topics: Aldosterone; Animals; Anticonvulsants; Brain; Diazepam; Disease Models, Animal; Dogs; Electroencepha

1975
Reactive and reparative myocardial fibrosis in arterial hypertension in the rat.
    Cardiovascular research, 1992, Volume: 26, Issue:7

    Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen; Disease Models, Animal; Fibrosis; Hype

1992
Aldosterone reduces baroreceptor discharge in the dog.
    Hypertension (Dallas, Tex. : 1979), 1992, Volume: 19, Issue:3

    Topics: Aldosterone; Animals; Blood Pressure; Disease Models, Animal; Dogs; Endothelium, Vascular; Female; H

1992
Prevention of various forms of metabolic myocardial necrosis by catatoxic steroids.
    Journal of molecular and cellular cardiology, 1970, Volume: 1, Issue:1

    Topics: Animals; Cardiomyopathies; Desoxycorticosterone; Digitoxin; Disease Models, Animal; Ethylestrenol; F

1970
Biliary excretion of mercury enhanced by spironolactone.
    Gastroenterology, 1972, Volume: 63, Issue:6

    Topics: Animals; Bile; Disease Models, Animal; Dose-Response Relationship, Drug; Erythrocytes; Kidney; Liver

1972
Differential effect of spironolactone on the ulcerogenic and anti-inflammatory activities of indomethacin.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1970, Volume: 135, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Arthritis; Disease Models, Animal; Indomethacin; Intestines; Male

1970